AI Article Synopsis
- The introduction of bicyclic 4-nitroimidazole and oxazolidinone antimicrobial agents marks significant progress in treating infectious diseases over the last two decades.
- Pretomanid and linezolid, two such agents, have been approved by the FDA for a combination therapy for difficult cases of multidrug-resistant tuberculosis (TB).
- New dual-acting nitroimidazole-oxazolidinone conjugates are being developed to combat antibiotic resistance and have shown promising results against various harmful anaerobic bacteria.
Article Abstract
The introductions of the bicyclic 4-nitroimidazole and the oxazolidinone classes of antimicrobial agents represented the most significant advancements in the infectious disease area during the past two decades. Pretomanid, a bicyclic 4-nitroimidazole, and linezolid, an oxazolidinone, are also part of a combination regimen approved recently by the US Food and Drug Administration for the treatment of pulmonary, extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) (TB). To identify new antimicrobial agents with reduced propensity for the development of resistance, a series of dual-acting nitroimidazole-oxazolidinone conjugates were designed, synthesized and evaluated for their antimicrobial activity. Compounds in this conjugate series have shown synergistic activity against a panel of anaerobic bacteria, including those responsible for serious bacterial infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288012 | PMC |
| http://dx.doi.org/10.3390/molecules25102431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!